Go Pro
→ Your withdrawal order could cost you in taxes (From SmartAsset) (Ad)tc pixel
NASDAQ:OCGN

Ocugen Q2 2026 Earnings Report

Ocugen logo
$1.23 -0.03 (-2.38%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$1.24 +0.01 (+0.41%)
As of 07/31/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Ocugen EPS Results

Actual EPS
N/A
Consensus EPS
-$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

Ocugen Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.98 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ocugen Announcement Details

Quarter
Q2 2026
Date
8/6/2026
Time
Before Market Opens
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Ocugen Earnings Headlines

Ocugen to Participate in Upcoming August Investor Conferences
July 31 at 11:43 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ocugen-participate-upcoming-august-investor-110200107.html
Ocugen to Present Modifier Gene Therapy Platform at Upcoming August 2026 Investor Conferences
July 31 at 7:30 AM  |  quiverquant.comQ
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
August 2 at 1:00 AM  |  Altimetry (Ad)
Ocugen to Participate in Upcoming August Investor Conferences
July 31 at 7:02 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336726/0/en/ocugen-to-participate-in-upcoming-august-investor-conferences.html
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy ...
July 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/ocugen-announces-that-the-u-s-food-and-drug-administration-has-granted-ocu410-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-geographic-atrophy-secondary-to-dry-1036377643
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ocugen-announces-u-food-drug-110100124.html
See More Ocugen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ocugen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocugen and other key companies, straight to your email.

About Ocugen

Ocugen (NASDAQ:OCGN) Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders. Lead candidates include OCU400 for retinitis pigmentosa and OCU410 for wet age-related macular degeneration, each engineered to deliver functional genetic material to retinal cells. The company’s approach is rooted in adeno-associated viral (AAV) vector technology, which has the potential to enable single-administration treatments and durable therapeutic benefits for patients facing progressive vision loss.

On the vaccine front, Ocugen entered into a collaboration with India-based Bharat Biotech in mid-2020 to co-develop and commercialize the COVID-19 vaccine Covaxin in the United States and Canada. This partnership illustrates Ocugen’s ability to partner with established developers to bring critical vaccine candidates into North American regulatory pathways. The company is also exploring additional vaccine opportunities that may leverage its manufacturing and distribution networks.

Founded in 2014, Ocugen is led by President and Chief Executive Officer Dr. Shankar Musunuri, who co-founded the company with the goal of addressing conditions with limited or no treatment options. Under his leadership and that of an experienced management team, Ocugen continues to advance its pipeline through clinical trials and regulatory interactions, with a mission to deliver innovative therapies for patients worldwide.

View Ocugen Profile
Earnings Tools